Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant

J Med Virol. 2022 May;94(5):1876-1885. doi: 10.1002/jmv.27626. Epub 2022 Feb 3.

Abstract

COVID's Omicron variant has sparked a slew of concerns across the globe. This review aims to provide a brief overview of what we know about the Omicron variant right now. The new variant has been discovered in 149 countries across all six World Health Organization (WHO) regions since its discovery in South Africa on November 24, 2021 and became the dominant variant in the country in less than 3 weeks. The WHO has warned that the B.1.1.529 variant is spreading at an unprecedented rate, and has urged countries to prepare for the worst. Over the course of this time, researchers from Africa and around the world have uncovered a wealth of information about the virus's epidemiology and biological properties. Case numbers are increasing exponentially in hard-hit areas such as South Africa, United Kingdom, and USA (overtaking the delta variant), implying that the variant is highly transmissible. Initial research has provided some insights into the efficacy of vaccines against the Omicron variant and whether it produces major illness, however, much remains unknown, and additional work is needed to investigate what the initial reports represent in real-world situations.

Keywords: B.1.1.529 variant; COVID-19; Omicron; SARS-Cov-2 coronavirus; transmission rate.

Publication types

  • Review

MeSH terms

  • COVID-19* / epidemiology
  • Humans
  • SARS-CoV-2* / genetics
  • South Africa / epidemiology
  • World Health Organization

Supplementary concepts

  • SARS-CoV-2 variants